Cut-points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice.

ABSTRACT: Plasma biomarkers for Alzheimer's disease (AD), such as plasma phosphorylated (p)-tau217, offer a more accessible means of testing for the presence of AD pathology compared to cerebrospinal fluid (CSF) or positron emission tomography (PET) methods. They can support diagnostic assessment and determine patient eligibility for treatment with amyloid beta-lowering drugs in community settings where access to CSF examination and amyloid-PET are limited. However, there are important challenges associated with interpreting and integrating plasma biomarker results in clinical practice. This article explores different approaches to interpreting plasma biomarker results in secondary care, important potential sources of uncertainty, and considerations for their clinical application. HIGHLIGHTS: Plasma

SUBMITTER: Hazan J 

PROVIDER: S-EPMC11947736 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature